The feline immunodeficiency virus (FIV) provides an excellent model system for AIDS vaccination studies. In the present experiments we investigated the immunogenicity and the protective activity of two inactivated vaccines prepared from a primary virus isolate. One vaccine was composed of whole virus inactivated with paraformaldehyde and then purified (WIV) and the other of viral proteins extracted with Tween-ether (TEV). Both vaccines elicited robust antiviral responses, but neither conferred appreciable levels of resistance against systemic challenge with the homologous virus. In addition, we tested whether the WIV vaccine, that had appeared more immunogenic, could protect against nontraumatic intravaginal exposure to FIV-infected cells. Although the proportions of control and vaccinated animals that became infected following mucosal challenge were similar, the vaccinees had significantly lower viral burdens than the controls: thus suggesting that immunisation with the WIV vaccine had limited FIV replication following intravaginal challenge. (C) 1999 Elsevier Science Ltd. All rights reserved.

AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viral replication following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus

MATTEUCCI, DONATELLA
Methodology
;
PISTELLO, MAURO
Writing – Original Draft Preparation
;
BENDINELLI, MAURO
Writing – Review & Editing
1999

Abstract

The feline immunodeficiency virus (FIV) provides an excellent model system for AIDS vaccination studies. In the present experiments we investigated the immunogenicity and the protective activity of two inactivated vaccines prepared from a primary virus isolate. One vaccine was composed of whole virus inactivated with paraformaldehyde and then purified (WIV) and the other of viral proteins extracted with Tween-ether (TEV). Both vaccines elicited robust antiviral responses, but neither conferred appreciable levels of resistance against systemic challenge with the homologous virus. In addition, we tested whether the WIV vaccine, that had appeared more immunogenic, could protect against nontraumatic intravaginal exposure to FIV-infected cells. Although the proportions of control and vaccinated animals that became infected following mucosal challenge were similar, the vaccinees had significantly lower viral burdens than the controls: thus suggesting that immunisation with the WIV vaccine had limited FIV replication following intravaginal challenge. (C) 1999 Elsevier Science Ltd. All rights reserved.
Matteucci, Donatella; Pistello, Mauro; Mazzetti, P.; Giannecchini, S.; Isola, P.; Merico, A.; Zaccaro, L.; Rizzuti, A.; Bendinelli, Mauro
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11568/204989
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 21
social impact